Richard LeBlanc

8PUBLICATIONS
34CO-AUTHORS
HaematologyGene and molecular therapyRegenerative medicine (incl. stem cells)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 22, 2026
Reversible Neutrophilia Driven by Monoclonal Gammopathy of Clinical Significance Simulating Chronic Neutrophilic Leukemia: A Case Report.

|Apr 25, 2025
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.

Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard

|Nov 26, 2024
A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.

Richard LeBlanc, Stéphanie Thiant, Rafik Terra

|Aug 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.

Richard LeBlanc, Hira Mian, Donna Reece

|Mar 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.

Arleigh McCurdy, Christopher P Venner, Esther Masih-Khan

|Nov 30, 2021
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.

Richard LeBlanc, Imran Ahmad, Rafik Terra

Pageof 2

Frequent Collaborators

4 joint publications

Jean Roy

3 joint publications

Imran Ahmad

3 joint publications

Jean-Sébastien Claveau

2 joint publications

Silvy Lachance